Skip to main content

Liposarcoma clinical trials at UC Health
1 research study open to eligible people

  • Selinexor in Advanced Liposarcoma

    open to eligible people ages 12 years and up

    This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

    at UCLA

Last updated: